Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.

A novel 5-phenylamino-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione series of MEK inhibitors has been developed using structure-based drug design. Lead optimization of this series led to the discovery of TAK-733. This was advanced to Phase I clinical studies for cancer treatment.

[1]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[2]  S. Shuto,et al.  Alternative synthesis of cyclic IDP-carbocyclic ribose. Efficient cyclization of an 8-bromo-N1-[5-(phosphoryl)carbocyclic-ribosyl]inosine 5′-phenylthiophosphate derivative mediated by iodine , 1999 .

[3]  R. Hamatake,et al.  RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. , 2009, Cancer research.

[4]  J. Lyssikatos,et al.  Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. , 2005, Current topics in medicinal chemistry.

[5]  J. Lyssikatos,et al.  Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones. , 2006, Journal of medicinal chemistry.

[6]  Rongshi Li,et al.  Kinase Inhibitor Drugs , 2009 .

[7]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[8]  G. Piccialli,et al.  Synthesis of 4-N-alkyl and ribose-modified AICAR analogues on solid support , 2008 .

[9]  Shuto,et al.  An efficient synthesis of cyclic IDP- and cyclic 8-bromo-IDP-carbocyclic-riboses using a modified Hata condensation method to form an intramolecular pyrophosphate linkage as a key step. An entry to a general method for the chemical synthesis of cyclic ADP-ribose analogues , 2000, The Journal of organic chemistry.

[10]  J. Warmus,et al.  2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase). , 2008, Bioorganic & medicinal chemistry letters.

[11]  N. Dumaz,et al.  Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways , 2005, The FEBS journal.

[12]  C. Der,et al.  KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer , 2009, Molecular Cancer Therapeutics.

[13]  Laura M. Heiser,et al.  Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.

[14]  J. Sebolt-Leopold,et al.  Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. , 2002, Trends in molecular medicine.

[15]  E. Krebs,et al.  The MAPK signaling cascade , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  J. Lyons,et al.  Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. , 2005, Current opinion in pharmacology.

[17]  C. Sander,et al.  V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.

[18]  G. Robertson,et al.  Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. , 2006, Cancer research.

[19]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[20]  S. Barrett,et al.  Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. , 2007, Arthritis and rheumatism.

[21]  S. Mu,et al.  The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker , 2009, Clinical Cancer Research.

[22]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[23]  Daniel F Ortwine,et al.  4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase. , 2007, Journal of medicinal chemistry.

[24]  A. Doherty,et al.  The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. , 2008, Bioorganic & medicinal chemistry letters.

[25]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.